HowardKaufmanMD

PubMed

• 4 citations
  Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy.
  Hongbin Wang, Mia Borlongan, Akseli Hemminki, Saru Basnet, Naresh Sah, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha> ;Human Gene Therapy. 2023 Sep 1
• 1 citations
  Attenuated Dengue virus PV001-DV induces oncolytic tumor cell death and potent immune responses.
  Josef W Goldufsky, Preston Daniels, Michael D Williams, Kajal Gupta, Bruce Lyday, Tony Chen, Geeta Singh, Howard L Kaufman, Andrew Zloza, Amanda L Marzo> ;Journal of Translational Medicine. 2023 Jul 19
• 1 citations
  Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.
  Jhawar, S., Wang, S., Thandoni, A., Bommareddy, P., Newman, J., Marzo, A., Kuzel, T., Gupta, V., Reiser, J., Daniels, P., Schiff, D., Mitchell, D., LeBoeuf, N., Simmon...> ;Journal for Immunotherapy of Cancer. 2023 Jul 1
• 1 citations
  Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort s...
  Bonnie W Leung, Guihong Wan, Nga Nguyen, Hannah Rashdan, Shijia Zhang, Wenxin Chen, Sonia Cohen, Genevieve M Boland, Ryan J Sullivan, Riley M Fadden, Howard L Kaufman,...> ;Journal of the American Academy of Dermatology. 2023 Jun 1
• Surgical factors affecting regionally metastatic cutaneous squamous cell carcinoma to the parotid gland.
  Vishwanatha M Rao, Allen L Feng, Daniel G Deschler, Howard L Kaufman, Derrick T Lin, David Miller, Jeremy D Richmon, Sophia Z Shalhout, Mark A Varvares, Kevin S Emerick> ;Head & Neck. 2023 May 1
• 8 citations
  Intratumorally anchored cytokine therapy.
  K Dane Wittrup, Howard L Kaufman, Michael M Schmidt, Darrell J Irvine> ;Expert Opinion on Drug Delivery. 2022 Jun 1
• 12 citations
  Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes.
  Sophia Z Shalhout, Howard L Kaufman, Kevin S Emerick, David M Miller> ;Clinical Cancer Research. 2022 Jun 1
• 15 citations
  Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class.
  Howard L Kaufman, Sophia Z Shalhout, Gail Iodice> ;Frontiers in Molecular Biosciences. 2022 Jan 1
• 2 citations
  Clinical utility of cell-free DNA liquid biopsies in Merkel cell carcinoma.
  Sophia Z Shalhout, Kevin Emerick, Howard L Kaufman, David M Miller> ;Dermatology Online Journal. 2021 Oct 15
• 3 citations
  Oncolytic Immunotherapy.
  Morgan L Hennessy, Praveen K Bommareddy, Genevieve Boland, Howard L Kaufman> ;Surgical Oncology Clinics of North America. 2019 Jul 1
• Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV ...
  Andtbacka, RHI.,Collichio, F.,Harrington, K. J.,Middleton, M. R.,Downey, G.,Ӧhrling, K.,Kaufman, H. L.> ;J Immunother Cancer. 2019 Jun 07
• Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma.
  Bommareddy, P. K.,Zloza, A.,Rabkin, S. D.,Kaufman, H. L.> ;Oncoimmunology. 2019 May 31
• Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial...
  Bommareddy, P. K.,Lowe, D. B.,Kaufman, H. L.,Rabkin, S. D.,Saha, D.> ;J Biol Methods. 2019 May 28
• 63 citations
  The promise of Immuno-oncology: implications for defining the value of cancer treatment.
  Howard L. Kaufman, Michael B. Atkins, Prasun Subedi, James Wu, James D. Chambers, T. Joseph Mattingly, Jonathan D. Campbell, Jeff Allen, Andrea Ferris, Richard L. Schi...> ;Journal for Immunotherapy of Cancer. 2019 Dec 1
• Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
  Bedognetti, D.,Ceccarelli, M.,Galluzzi, L.,Lu, R.,Palucka, K.,Samayoa, J.,Spranger, S.,Warren, S.,Wong, K. K.,Ziv, E.,Chowell, D.,Coussens, L. M.,De Carvalho, D. D.,De...> ;J Immunother Cancer. 2019 May 23
• HASH(0x37bd2e0)
  Fishman, M.,Dutcher, J. P.,Clark, J. I.,Alva, A.,Miletello, G. P.,Curti, B.,Agarwal, N.,Hauke, R.,Mahoney, K. M.,Moon, H.,Treisman, J.,Tykodi, S. S.,Daniels, G.,Morse,...> ;J Immunother Cancer. 2019 Mar 29
• 3 citations
  Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).
  Paolo A Ascierto, James Brugarolas, Luigi Buonaguro, Lisa H Butterfield, David Carbone, Bruno Daniele, Robert Ferris, Bernard A Fox, Jérôme Galon, Cesare Gridelli, How...> ;Journal for Immunotherapy of Cancer. 2018 Jul 11
• Updated Efficacy of Avelumab in Patients with Previously Treated Metastatic Merkel Cell Carcinoma After ≥1 Year of Follow-up: JAVELIN Merkel 200, a Phase 2 Clinical Trial
  Howard L. Kaufman, Shailender Bhatia, Jochen H. Lorch, Kent C. Shih, Omid Hamid, Karl D. Lewis, Howard L Kaufman> ;BioMed Central.
• High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.
  Marabondo, S.,Kaufman, H. L.> ;Expert Opin Drug Saf. 2017 Sep 21
• 24 citations
  Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.
  Brendan D. Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, Meenu Kaur, Theresa L. Luna, Nancy C. ...> ;Journal for Immunotherapy of Cancer. 2017 Dec 19
• 1211 citations
  Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Wor...
  Igor Puzanov, Adi Diab, K. Abdallah, Clifton O. Bingham, C. Brogdon, Ramona Dadu, Lamya Hamad, Sang Taek Kim, Mario E. Lacouture, Nicole R. LeBoeuf, D. Lenihan, C. Ono...> ;Journal for Immunotherapy of Cancer. 2017 Nov 21
• 410 citations
  Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients...
  Jason Chesney, Igor Puzanov, Frances A. Collichio, Parminder Singh, Mohammed M. Milhem, John A. Glaspy, Omid Hamid, Merrick I. Ross, Philip Friedlander, Claus Garbe, T...> ;Journal of Clinical Oncology. 2017 Oct 5
• Finding Gold in Tumour Immunotherapy
  Howard Kaufman, MD> ;The Lancet. 2017 Oct 04
• 25 citations
  Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinom...
  Joseph I. Clark, Michael K.K. Wong, Howard L. Kaufman, Gregory A. Daniels, Michael A. Morse, David F. McDermott, Sanjiv S. Agarwala, Lionel D. Lewis, John H. Stewart, ...> ;Clinical Genitourinary Cancer. 2017 Feb 1
• Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma.
  Zloza, A.,Dharmadhikari, N. D.,Huelsmann, E. J.,Broucek, J. R.,Hughes, T.,Kohlhapp, F. J.,Kaufman, H. L.> ;Cancer Immunol. Immunother.. 2016 Oct 21
• Join now to see all

Journal Articles

• Author Correction: Integrating Oncolytic Viruses in Combination Cancer Immunotherapy  
  Howard Kaufman, MD, Nature